LONDON: Frontier IP’s portfolio company Exscientia, a world leader in artificial intelligence (AI) drug discovery, has entered into a drug-discovery partnership with GT Apeiron Therapeutics.
GT Apeiron is a Shanghai-headquartered biotechnology drug-discovery platform launched with US$27 million backing from GT Healthcare Capital Partners, a life sciences-focused private equity partnership. GT Healthcare is also an investor in Exscientia. [the_ad id=”31605″]As part of the agreement, Exscientia is entitled to become a shareholder in GT Apeiron as well as receiving milestones and royalties based on the clinical and commercial success of each programme.
GT Healthcare invested in Exscientia as part of a Series B financing round, which raised US$26 million to scale up the Company’s pipeline and advance selected programmes towards clinical development. Further details were announced by Frontier IP on 7 January 2019.
Exscientia’s existing partnerships include collaborations with Celgene, GSK, Roche, Sanofi and Evotec. Frontier IP holds a 3.32 per cent stake in the Company.